Citicoline (CDP-Choline): What the Human Evidence Actually Supports

Reviewed by the NootropicsJet editorial team · Published: [11-07-2024] · Last updated: [14-08-2026]

Based on published human randomized controlled trials, the 2024 EFSA scientific opinion on citicoline and memory, and EU novel food authorization documents. Every citation carries a PMID, DOI or official document reference.

---

Citicoline is one of the few nootropic compounds with a genuine clinical trial record — and one of the few where that record includes two large, well-run failures and a regulatory rejection. This article covers what citicoline is, what happens to it after you swallow it, which cognitive outcomes have actually been measured in humans, the doses used in those studies, and where the evidence stops.

Key takeaways

• Oral citicoline is not absorbed intact. It is hydrolyzed to choline and cytidine, and in humans the cytidine arrives at the brain largely as uridine — a species difference most nootropic coverage gets wrong.
• The best trial in healthy people is narrower than it is usually reported. A 12-week randomized trial at 500 mg/day found improved episodic memory in adults aged 50–85 with age-associated memory impairment — and the finding was a secondary outcome, not the primary one.
• EFSA rejected the memory health claim in 2024. The panel concluded that a cause-and-effect relationship has not been established between citicoline and memory in middle-aged or elderly adults with age-associated subjective memory impairment.
• Two large clinical trials were null. Citicoline failed in acute ischemic stroke (n = 2,298) and in traumatic brain injury (n > 1,200), both at 2,000 mg/day. Any honest account has to include them.
• Nearly all healthy-population research uses one branded ingredient, and the manufacturer is involved. Cognizin trials include Kyowa Hakko Bio staff as co-authors. That does not make them wrong; it belongs in your calculation.
• EU law caps food supplements at 500 mg/day and prohibits citicoline in foods intended for children.

What is citicoline?

Citicoline is the common name for cytidine 5′-diphosphocholine — usually shortened to CDP-choline. It is a genuine human metabolite, not a synthetic analog: it sits in the middle of the Kennedy pathway, the route cells use to build phosphatidylcholine, the dominant phospholipid in neuronal membranes.

That middle position matters. CDP-choline is an intermediate, not a storage form. Cells make it, consume it, and don’t stockpile it. Supplementing it is not topping up a reservoir — it is supplying substrate to a pathway whose rate can, in principle, be limited by precursor availability.

Two things get made downstream: phosphatidylcholine, for membranes, and acetylcholine, the neurotransmitter most closely tied to attention and the encoding of new memories.

Citicoline is sold as a dietary supplement in the US and EU. In several countries, including Japan and parts of Europe, it has also been used as a prescription drug at higher doses. Those are different regulatory categories with different evidence bases, and this article keeps them separate.

How does citicoline work in the brain?

Oral citicoline is almost completely broken down before it reaches circulation. It is hydrolyzed in the gut wall and liver into choline and cytidine, both of which are absorbed, and intact CDP-choline is then resynthesized inside cells.

This means citicoline delivers two distinct payloads, and the second is where most popular coverage goes wrong.

The choline arm

Choline crosses the blood-brain barrier and feeds two pathways: phosphatidylcholine synthesis and acetylcholine synthesis. Acetylcholine availability is relevant to sustained attention and memory encoding — field consensus from decades of cholinergic pharmacology, not a citicoline-specific finding.

If your interest is raw choline delivery, citicoline is one of several options and not the most efficient per milligram. Alpha-GPC delivers a higher percentage of choline by weight. We cover that trade-off in our citicoline vs alpha-GPC comparison — this article deliberately doesn’t repeat it.

The cytidine arm — and why it’s uridine in humans

Rodents readily use circulating cytidine. Humans mostly don’t. In humans, cytidine is rapidly deaminated to uridine, and uridine is the pyrimidine that reaches the brain in meaningful quantities.

Uridine is not a bystander. It is converted to UTP, then CTP, then back into CDP-choline inside the neuron — closing the loop — and in preclinical models it supports synthesis of membrane phospholipids, synaptic proteins and dendritic spine density.

Two practical implications. First, any article claiming citicoline “supplies cytidine to your brain” is describing a rat. Second, the uridine arm is the honest answer to “why not just take cheap choline bitartrate” — citicoline is a choline source plus a pyrimidine source, and the pyrimidine half is a real pharmacological difference.

Whether that difference produces a difference you can feel is a separate question. EFSA’s 2024 assessment is blunt on this point: no convincing evidence of a plausible mechanism by which citicoline or any of its components — in addition to their endogenous synthesis — could exert an effect on memory in humans was provided (EFSA NDA Panel, 2024, EFSA Journal, doi:10.2903/j.efsa.2024.8861).

Evidence tier: Mechanistic (Tier 4) for the downstream synaptic effects. The pharmacokinetics are well characterized; the claim that the uridine arm improves cognition in healthy people has not been isolated and tested.

Does citicoline work? What the human trials show

The best study in healthy people, read precisely

Nakazaki et al., 2021, The Journal of Nutrition 151(8):2153–2160 — randomized, double-blind, placebo-controlled parallel trial in the USA. 100 participants aged 50–85 with age-associated memory impairment (AAMI), randomized to 500 mg/day Cognizin citicoline (n = 49) or placebo (n = 51) for 12 weeks. 99 completed.

Two details matter and are almost universally dropped in summaries:

1. The population was not simply “healthy older adults.” Participants were screened for age-associated memory impairment — people who already had subjective and measurable memory decline.
2. The positive finding was a secondary outcome. Participants on citicoline showed significantly greater improvement in episodic memory, assessed by the Paired Associate test, listed among the study’s secondary outcomes.

The trial used Cognizin manufactured by Kyowa Hakko Bio, and the lead author is a researcher at the Kirin Central Research Institute — Kirin Holdings is Kyowa Hakko Bio’s parent company. This is not concealed; it is disclosed in the publication and in the manufacturer’s own press materials. It is a direct commercial relationship, not arm’s-length sponsorship, and readers should weigh it accordingly.

Tier 2 — Moderate, with the population caveat attached. Human trial evidence suggests a memory benefit in older adults who already have age-related memory impairment. This is the opposite of how citicoline is usually marketed.

The regulatory verdict nobody quotes

In 2024 the EFSA Panel on Nutrition, Novel Foods and Food Allergens evaluated a health claim application for citicoline and memory, submitted via the Polish competent authority.

The applicant identified three human intervention studies in healthy individuals. The Panel’s conclusion: a cause-and-effect relationship has not been established between the consumption of citicoline (CDP-Choline) inner salt and improvement, maintenance or reduced loss of memory in middle-aged or elderly adults encountering age-associated subjective memory impairment.

Their reasoning is instructive. Only one randomized controlled trial in healthy participants showed a beneficial effect on episodic memory at 500 mg/day for 12 weeks. That effect was not observed in another study using 1 g/day for three months, nor supported by data in patients with dementia at 1 g/day over 12 weeks and 12 months.

That is an independent regulator, with access to the full dossier, declining to authorize the exact claim this compound is sold on. It does not mean citicoline does nothing. It means the evidence is not strong enough for a regulated health claim, and any confident promise you read is exceeding what the data supports.

Healthy younger adults and attention

Two trials, both using Cognizin, both with manufacturer staff among the co-authors:

• McGlade et al., 2012, Food and Nutrition Sciences 3:769–773 — 60 healthy women aged 40–60, 250 or 500 mg/day for 28 days. Improved attentional performance on the Ruff 2 & 7 Selective Attention Test and CPT-II. Note the journal: Food and Nutrition Sciences is a low-tier publication, which is a meaningful quality signal.
• McGlade et al., 2019, Journal of Attention Disorders 23(2):121–134, PMID 26179181 — 75 healthy adolescent males, citicoline group n = 51 (250 or 500 mg), placebo n = 24, 28 days. Improved attention (p = 0.02) and psychomotor speed (p = 0.03) versus placebo. Higher weight-adjusted dose predicted greater attentional accuracy (p = 0.01) and reduced impulsivity (p = 0.01).

Tier 3 — Preliminary. Early evidence indicates a small attention effect at 250–500 mg/day over four weeks. Neither trial has been independently replicated by a group without manufacturer involvement.

Worth noting for anyone considering citicoline for a student: the adolescent trial is the only one in a young population, it was 28 days, and it measured attention and motor speed — not learning or retention.

The clinical literature, and two null results

Citicoline’s reputation was built largely on European and Japanese clinical research in stroke, which produced early positive pooled analyses. Then came the definitive tests.

ICTUS (Dávalos et al., 2012, The Lancet 380(9839):349–357, PMID 22691567) — international, randomized, multicentre, placebo-controlled. 2,298 patients with moderate-to-severe acute ischemic stroke, 2,000 mg/day for six weeks. The trial was stopped for futility at the third interim analysis. Global recovery was similar in both groups (odds ratio 1.03, 95% CI 0.86–1.25; p = 0.364). The authors’ conclusion: under the circumstances of the trial, citicoline is not efficacious in moderate-to-severe acute ischemic stroke. Funded by Ferrer Grupo.

A second large trial in traumatic brain injury, treating over 1,200 patients with 2,000 mg/day for 90 days, likewise found no improvement in memory, attention or functional recovery versus placebo.

Two things follow. Findings in acutely ill patients receiving pharmaceutical doses under medical supervision tell you very little about a supplement in a healthy person — the populations, doses and outcomes are not comparable. And a compound whose flagship clinical indications failed their largest trials deserves calibrated expectations everywhere else.

Nothing in this section is a claim that citicoline treats, prevents or mitigates stroke, brain injury or any other condition. It does not, and it is not sold for that purpose.

Evidence strength at a glance

Citicoline dosage: what’s used in research

Published human trials in healthy people use 250–500 mg per day, for 28 days to 12 weeks. Clinical research in patient populations has used 1,000–2,000 mg/day under medical supervision — the doses that failed in the large trials above.

Regulatory ceiling. Commission Implementing Decision 2014/423/EU authorizes citicoline in the EU as a novel food ingredient in food supplements at a maximum of 500 mg per day, and in foods for special medical purposes at 250 mg per serving with a maximum daily intake of 1,000 mg from these foods. Citicoline shall not be used in foods intended for children. In the US, citicoline holds self-affirmed GRAS status at 250 mg per serving.

Practical reading: 250 mg is a legitimate starting dose with trial support. Doses above 500 mg belong to the clinical literature, not the supplement aisle — and in that literature they did not work.

How long does citicoline take to work?

Every positive trial in healthy people ran a minimum of 28 days before measuring outcomes; none tested acute single-dose cognitive effects as a primary endpoint. Some users report same-day subjective effects, but no controlled trial supports an acute benefit. Plan a four-week minimum trial and judge it at six to eight weeks.

When should you take citicoline?

No trial has directly compared morning versus evening dosing. Because cholinergic activity and reported insomnia are the practical considerations, morning or early-afternoon dosing with food is the sensible default. The Nakazaki trial dosed at breakfast. Splitting 500 mg into two 250 mg doses is reasonable but untested.

Forms, bioavailability, and reading a label

Two forms dominate: generic citicoline sodium and Cognizin, the branded form manufactured by Kyowa Hakko Bio. Cognizin is the material used in essentially all of the healthy-population trials cited above — which is a real argument in its favor, since you would be buying the substance that was actually studied, and simultaneously the reason those trials carry a commercial-involvement footnote.

A quality citicoline product, judged on criteria rather than marketing:

• Form stated explicitly. “Citicoline (as Cognizin)” or “citicoline sodium,” not “choline complex.”
• Active dose disclosed per serving, with citicoline content specified if a sodium salt is used.
• No proprietary blends. If citicoline is buried inside a 1,200 mg “focus matrix,” you cannot know whether you are getting 250 mg or 25 mg.
• Third-party testing for identity and contaminants, with a batch-specific certificate of analysis available.
• Dose within the studied range — 250–500 mg. A product boasting 1,000 mg is exceeding the supplement evidence base and the EU regulatory ceiling, not improving on either.

Those five criteria eliminate most of the shelf.

Safety, side effects and interactions

Citicoline has a good tolerability record at supplement doses. Reported adverse effects in trials are mild and uncommon: gastrointestinal upset, headache, insomnia, and occasionally reduced appetite. In the Nakazaki trial, no adverse events were deemed definitely or probably related to the study product, and there were no significant between-group differences in hematology or metabolic panels. In ICTUS, at ten times the supplement dose, adverse event rates were comparable between citicoline and placebo.

Interactions to raise with a clinician, by drug class:

• Cholinesterase inhibitors — additive cholinergic effects are plausible.
• Anticholinergic medications, including some antihistamines, bladder medications and tricyclics — pharmacologically opposed mechanisms.
• Dopaminergic medications for Parkinson’s disease — citicoline has been studied alongside levodopa in clinical settings, meaning the combination is not neutral and warrants supervision.
• Meclofenoxate (centrophenoxine) — listed as a contraindication in citicoline drug monographs.

EFSA’s safety opinion supporting the novel food authorization specifically noted that citicoline should not be consumed alongside certain medicines, and never by children.

Who should avoid citicoline:

• Anyone pregnant or breastfeeding — no adequate safety data at supplemental doses.
• Children and under-18s — EU authorization explicitly excludes foods intended for children.
• Anyone taking the drug classes above, without clinical input.
• Anyone with a diagnosed neurological or psychiatric condition — the clinical literature involves prescribing decisions, not self-experimentation.

If any of these describe you, speak to a qualified healthcare professional before starting.

Stacking: what’s supported and what’s assumption

Citicoline combines sensibly with compounds that increase demand on attention systems rather than duplicating its mechanism. The most common pairings are caffeine plus L-theanine, and racetams — the latter on the reasoning that racetams increase cholinergic turnover and citicoline supplies substrate. That reasoning is plausible and largely untested in controlled trials; it belongs in Tier 4 until someone runs the study.

If you are building a study or work stack, our nootropic stack for studying guide covers sequencing, and readers avoiding stimulants may find our guide to caffeine-free options for clean focus more useful than adding another compound.

Citicoline sits in the broader family of cholinergic and membrane-support compounds covered across the wider field of nootropics and cognitive enhancers.

A protocol for testing whether it works for you

Group-level trial results tell you what happened on average to 100 people, most of whom were older than you and already experiencing memory decline. Since citicoline’s plausible effects are on attention and memory — both measurable — you can run a reasonable self-test:

1. Pick one outcome, not five. Sustained attention or delayed recall. Not “brain fog.”
2. Baseline for one week before dosing. A repeatable task at a consistent time of day — a timed task from your actual work, or a spaced-repetition app’s retention percentage.
3. Dose 250–500 mg daily for 28 days. Change nothing else.
4. Measure in weeks 4 and 6. Compare to your baseline week, not to how you feel.
5. Log side effects daily — especially sleep quality, the most common reason people quit.
6. Decide on the data. If your metric hasn’t moved by week 6, it isn’t working for you. Stop. There is no dependency or withdrawal profile that makes discontinuation difficult.

For readers focused on the memory side, our guide to improving working memory covers non-supplement interventions with larger effect sizes than anything discussed here.

What we still don’t know

• Whether the uridine arm matters in practice. No trial has compared citicoline against an equivalent dose of choline alone. “Citicoline is better than plain choline” remains a mechanistic argument.
• Whether it does anything in people without existing memory impairment. The one positive memory trial screened specifically for AAMI.
• Why higher doses performed worse. 500 mg for 12 weeks showed an effect; 1 g/day for three months did not. Dose-response has not been mapped and the inversion is unexplained.
• Whether effects persist beyond 12 weeks. No long-term controlled data in healthy people.
• Independent replication of any healthy-population finding by a group without manufacturer involvement.

The bottom line

Citicoline is a legitimate compound with a real, if modest and contested, human evidence base — which puts it in the top decile of the nootropic market simply by having been tested at scale.

The defensible summary: one qualified positive trial for episodic memory in older adults who already have age-related memory impairment, preliminary evidence for attention in healthy people, a 2024 EFSA determination that cause and effect has not been established, and two large null trials at clinical doses.

Who this isn’t for. A healthy 25-year-old expecting a noticeable lift in focus. The honest expectation is a small effect you may not detect without measuring, arriving after four weeks — and the trial population that showed the clearest benefit was forty years older with diagnosed memory impairment. If your sleep is broken or your workload is the actual problem, citicoline will not fix either.

Who it makes sense for. Adults over 50 noticing age-related memory changes, with 500 mg/day for 12 weeks as the research-matched protocol. Readers already running a cholinergic stack who want a substrate with human data behind it. Anyone who wants a low-risk compound they can test properly and abandon cleanly.

If you decide to test it, use the five label criteria above, run the 28-day protocol, and judge it on your own data. If you would rather read before you buy, the citicoline vs alpha-GPC comparison is the logical next step.

Frequently asked questions

Does citicoline actually work? Partially, and less broadly than marketed. One 12-week randomized trial at 500 mg/day found improved episodic memory in adults aged 50–85 with age-associated memory impairment — as a secondary outcome (Nakazaki et al., 2021). In 2024 EFSA reviewed the evidence and concluded a cause-and-effect relationship with memory has not been established. Attention findings in healthy adults are preliminary.

How long does citicoline take to work? Plan on four weeks minimum. Every published trial in healthy people dosed for at least 28 days before measuring cognitive outcomes, and the best-designed one ran 12 weeks. No controlled trial has demonstrated an acute single-dose cognitive effect.

What is the best citicoline dosage? Research in healthy people uses 250–500 mg per day. EU law caps food supplements at 500 mg/day. Higher doses appear in clinical research under medical supervision — and at 2,000 mg/day citicoline failed its two largest trials, so more is not better here.

Can you take citicoline with caffeine? No trial has tested the combination directly. Mechanistically the two act on unrelated systems — adenosine antagonism versus cholinergic and phospholipid substrate supply — and no pharmacological conflict is expected. Take citicoline earlier in the day if you are sensitive to sleep disruption.

Does citicoline have side effects? Reported effects in trials are mild and uncommon: gastrointestinal upset, headache, insomnia and occasionally reduced appetite. In the 12-week trial, no adverse events were judged definitely or probably related to the product. Insomnia is the most frequent practical complaint; morning dosing usually resolves it.

Is citicoline better than alpha-GPC? They are different tools. Alpha-GPC delivers more choline by weight; citicoline supplies choline plus uridine and has more human trial data in healthy populations. Neither has been shown superior in a head-to-head trial. We break down the trade-offs in our citicoline vs alpha-GPC comparison.

Can you take citicoline long term? Unknown. The longest controlled trial in healthy people ran 12 weeks, so there is no controlled data beyond that in a healthy population. Citicoline has no known dependency or withdrawal profile, and no evidence requires cycling. Periodic breaks are a reasonable precaution rather than a supported protocol.

---

This article is for informational purposes only and is not medical advice. Citicoline is a dietary supplement and is not intended to diagnose, treat, cure or prevent any disease. Consult a qualified healthcare professional before starting any supplement, particularly if you are pregnant or breastfeeding, under 18, taking prescription medication, or managing a diagnosed condition.

---

---

REFERENCES

1. Nakazaki E, Mah E, Sanoshy K, Citrolo D, Watanabe F. Citicoline and memory function in healthy older adults: a randomized, double-blind, placebo-controlled clinical trial. J Nutr. 2021;151(8):2153–2160. doi:10.1093/jn/nxab119
2. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). ‘Citicoline’ and support of the memory function: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal. 2024. doi:10.2903/j.efsa.2024.8861
3. Dávalos A, Alvarez-Sabín J, Castillo J, et al.; ICTUS trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012;380(9839):349–357. doi:10.1016/S0140-6736(12)60813-7. PMID 22691567
4. McGlade E, Agoston AM, DiMuzio J, et al. The effect of citicoline supplementation on motor speed and attention in adolescent males. J Atten Disord. 2019;23(2):121–134. PMID 26179181
5. McGlade E, Locatelli A, Hardy J, et al. Improved attentional performance following citicoline administration in healthy adult women. Food Nutr Sci. 2012;3:769–773
6. Commission Implementing Decision 2014/423/EU of 1 July 2014 authorising the placing on the market of citicoline as a novel food ingredient under Regulation (EC) No 258/97